Mingjun Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mingjun Sun has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Hon Wai Koon
Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California
3 shared publications - Andrea Chupina Estrada
Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California, Los Angeles , Los Angeles, California , USA
2 shared publications - Ashlen Bullock
Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California, Los Angeles , Los Angeles, California , USA
2 shared publications - Becca Nelson
Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California, Los Angeles , Los Angeles, California , USA
2 shared publications - Hanping Feng
Department of Microbial Pathogenesis, University of Maryland at Baltimore, Baltimore, MD 21201, USA
2 shared publications - Hong Xu
Department of Gastroenterology, The First Hospital of Jilin University, ChangChun, China
2 shared publications
Latest Publications
- Open Access
- 8 April 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28 (1) , e78203
Machine Learning in Predicting the Risk of Esophagogastric Variceal Bleeding Among Patients With Liver Cirrhosis: Systematic Review and Meta-Analysis
Background: Liver cirrhosis (LC) can lead to several complications. Esophageal variceal bleeding (EVB) and esophagogastric variceal bleeding (EGVB) are particularly severe, leading to a high risk of mortality. Early identification of esophageal varices and esophagogastric varices is essential. Several studies have constructed prediction models for EVB and EGVB in patients with LC. However, robust systematic evidence to prove their performance is lacking. Objective: We included original studies that developed prediction models for esophageal or gastric variceal bleeding in patients with LC under different modeling variables. This study aimed to review the predictive performance of various models for EVB or EGVB in patients with LC, providing insights into the development or updating of simplified scoring tools in the future. Methods: PubMed, Web of Science, Embase, and the Cochrane Library were searched up to August 21, 2024, to collect original full-text studies on machine learning (ML) in the prediction of EVB and EGVB in patients with LC. The models were evaluated using the Prediction Model Risk of Bias Assessment Tool (PROBAST). Subgroup analyses were carried out based on the modeling variables. Results: In total, 21 studies were included, with 7011 patients with LC, among whom 1412 (20.14%) developed EVB and 733 (10.45%) developed EGVB. The meta-analysis results suggested that the pooled c-index, sensitivity, and specificity of the prediction model for predicting EVB in the validation set were 0.85 (95% CI 0.77‐0.92), 0.93 (95% CI 0.87‐0.96), and 0.66 (95% CI 0.46‐0.82), respectively. The pooled c-index, sensitivity, and specificity of the prediction model for predicting EGVB in the validation set were 0.89 (95% CI 0.85‐0.94), 0.77 (95% CI 0.66‐0.85), and 0.81 (95% CI 0.67‐0.90), respectively. The subgroup analysis based on modeling variables revealed that, for predicting EVB, the c-index in the validation set was 0.84 (95% CI 0.80‐0.88) for models based on clinical features, 0.82 (95% CI 0.69‐0.96) for radiomics-based models, 0.78 (95% CI 0.67‐0.89) for models based on radiomics and clinical features, and 0.97 (95% CI 0.95‐1.00) for models based on endoscopic features. Subgroup analyses based on modeling variables revealed that, for predicting EGVB, the c-index in the validation set was 0.91 (95% CI 0.86‐0.96) for models based on clinical features and 0.85 (95% CI 0.75‐0.96) for models based on radiomics and clinical features. Conclusions: ML methods are feasible for predicting EVB and EGVB in patients with LC. Nevertheless, the number of included original studies is limited. In the future, more studies with larger sample sizes are needed to promote the application of ML in the early assessment of EVB and EGVB in patients with LC in clinical practice.
- 8 April 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28 (1) , e78203
Open AccessMachine Learning in Predicting the Risk of Esophagogastric Variceal Bleeding Among Patients With Liver Cirrhosis: Systematic Review and Meta-Analysis
Background: Liver cirrhosis (LC) can lead to several complications. Esophageal variceal bleeding (EVB) and esophagogastric variceal bleeding (EGVB) are particularly severe, leading to a high risk of mortality. Early identification of esophageal varices and esophagogastric varices is essential. Several studies have constructed prediction models for EVB and EGVB in patients with LC. However, robust systematic evidence to prove their performance is lacking. Objective: We included original studies that developed prediction models for esophageal or gastric variceal bleeding in patients with LC under different modeling variables. This study aimed to review the predictive performance of various models for EVB or EGVB in patients with LC, providing insights into the development or updating of simplified scoring tools in the future. Methods: PubMed, Web of Science, Embase, and the Cochrane Library were searched up to August 21, 2024, to collect original full-text studies on machine learning (ML) in the prediction of EVB and EGVB in patients with LC. The models were evaluated using the Prediction Model Risk of Bias Assessment Tool (PROBAST). Subgroup analyses were carried out based on the modeling variables. Results: In total, 21 studies were included, with 7011 patients with LC, among whom 1412 (20.14%) developed EVB and 733 (10.45%) developed EGVB. The meta-analysis results suggested that the pooled c-index, sensitivity, and specificity of the prediction model for predicting EVB in the validation set were 0.85 (95% CI 0.77‐0.92), 0.93 (95% CI 0.87‐0.96), and 0.66 (95% CI 0.46‐0.82), respectively. The pooled c-index, sensitivity, and specificity of the prediction model for predicting EGVB in the validation set were 0.89 (95% CI 0.85‐0.94), 0.77 (95% CI 0.66‐0.85), and 0.81 (95% CI 0.67‐0.90), respectively. The subgroup analysis based on modeling variables revealed that, for predicting EVB, the c-index in the validation set was 0.84 (95% CI 0.80‐0.88) for models based on clinical features, 0.82 (95% CI 0.69‐0.96) for radiomics-based models, 0.78 (95% CI 0.67‐0.89) for models based on radiomics and clinical features, and 0.97 (95% CI 0.95‐1.00) for models based on endoscopic features. Subgroup analyses based on modeling variables revealed that, for predicting EGVB, the c-index in the validation set was 0.91 (95% CI 0.86‐0.96) for models based on clinical features and 0.85 (95% CI 0.75‐0.96) for models based on radiomics and clinical features. Conclusions: ML methods are feasible for predicting EVB and EGVB in patients with LC. Nevertheless, the number of included original studies is limited. In the future, more studies with larger sample sizes are needed to promote the application of ML in the early assessment of EVB and EGVB in patients with LC in clinical practice.
- Open Access
- 13 May 2024
- Published by Elsevier in Translational Oncology
- Vol. 45, 101992
CBLC promotes the development of colorectal cancer by promoting ABI1 degradation to activate the ERK signaling pathway
- 13 May 2024
- Published by Elsevier in Translational Oncology
- Vol. 45, 101992
Open AccessCBLC promotes the development of colorectal cancer by promoting ABI1 degradation to activate the ERK signaling pathway
- Open Access
- 19 January 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (3) , 545-557
Loratadine as an Anti-inflammatory Agent Against Clostridium difficile Toxin B
Loratadine is an FDA-approved antihistamine that inhibits toxin B-mediated pro-inflammatory macrophage inflammatory protein one alpha secretion from immune cells. The anti-inflammatory effect of Loratadine ameliorates intestinal inflammation in C. difficile-infected animals. Loratadine may be repurposed to optimize existing therapies.
- 19 January 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (3) , 545-557
Open AccessLoratadine as an Anti-inflammatory Agent Against Clostridium difficile Toxin B
Loratadine is an FDA-approved antihistamine that inhibits toxin B-mediated pro-inflammatory macrophage inflammatory protein one alpha secretion from immune cells. The anti-inflammatory effect of Loratadine ameliorates intestinal inflammation in C. difficile-infected animals. Loratadine may be repurposed to optimize existing therapies.
- 11 January 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 227 (6) , 806-819
Genistein Inhibits Clostridioides difficile Infection via Estrogen Receptors and Lysine-Deficient Protein Kinase 1
Clostridioides difficile infection (CDI) is a debilitating nosocomial disease. Postmenopausal women may have an increased risk of CDI, suggesting estrogen influence. Soybean products contain a representative estrogenic isoflavone, genistein. The anti-inflammatory and antiapoptotic effects of genistein were determined using primary human cells and fresh colonic tissues. The effects of oral genistein therapy among mice and hamsters were evaluated. Within 10 days of CDI, female c57BL/6J mice in a standard environment (regular diet) had a 50% survival rate, while those with estrogen depletion and in an isoflavone-free environment (soy-free diet) had a 25% survival rate. Oral genistein improved their 10-day survival rate to 100% on a regular diet and 75% in an isoflavone-free environment. Genistein reduced macrophage inflammatory protein-1α (MIP-1α) secretion in fresh human colonic tissues exposed to toxins. Genistein inhibited MIP-1α secretion in primary human peripheral blood mononuclear cells, abolished apoptosis and BCL-2–associated X (BAX) expression in human colonic epithelial cells, and activated lysine-deficient protein kinase 1 (WNK1) phosphorylation in both cell types. The anti-inflammatory and antiapoptotic effects of genistein were abolished by inhibiting estrogen receptors and WNK1. Genistein reduces CDI disease activity by inhibiting proinflammatory cytokine expression and apoptosis via the estrogen receptor/G-protein estrogen receptor/WNK1 pathways.
- 11 January 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 227 (6) , 806-819
Genistein Inhibits Clostridioides difficile Infection via Estrogen Receptors and Lysine-Deficient Protein Kinase 1
Clostridioides difficile infection (CDI) is a debilitating nosocomial disease. Postmenopausal women may have an increased risk of CDI, suggesting estrogen influence. Soybean products contain a representative estrogenic isoflavone, genistein. The anti-inflammatory and antiapoptotic effects of genistein were determined using primary human cells and fresh colonic tissues. The effects of oral genistein therapy among mice and hamsters were evaluated. Within 10 days of CDI, female c57BL/6J mice in a standard environment (regular diet) had a 50% survival rate, while those with estrogen depletion and in an isoflavone-free environment (soy-free diet) had a 25% survival rate. Oral genistein improved their 10-day survival rate to 100% on a regular diet and 75% in an isoflavone-free environment. Genistein reduced macrophage inflammatory protein-1α (MIP-1α) secretion in fresh human colonic tissues exposed to toxins. Genistein inhibited MIP-1α secretion in primary human peripheral blood mononuclear cells, abolished apoptosis and BCL-2–associated X (BAX) expression in human colonic epithelial cells, and activated lysine-deficient protein kinase 1 (WNK1) phosphorylation in both cell types. The anti-inflammatory and antiapoptotic effects of genistein were abolished by inhibiting estrogen receptors and WNK1. Genistein reduces CDI disease activity by inhibiting proinflammatory cytokine expression and apoptosis via the estrogen receptor/G-protein estrogen receptor/WNK1 pathways.
- 11 October 2021
- Published by Wiley in Journal of Digestive Diseases
- Vol. 22 (11) , 622-629
Efficacy and safety of lubiprostone for the treatment of functional constipation in Chinese adult patients: A multicenter, randomized, double‐blind, placebo‐controlled trial
Objectives: Functional constipation is a gastrointestinal disorder prevalent around the world. Lubiprostone is the first locally acting type‐2 chloride channel activator to be used for treating constipation. This study aimed to evaluate the efficacy and safety of lubiprostone in Chinese adults with functional constipation.Methods: This was a multicenter, randomized, double‐blind, placebo‐controlled study. Patients with functional constipation were randomized to receive either lubiprostone (24 mcg twice daily) or placebo for 4 weeks. The primary end‐point was the frequency of spontaneous bowel movements (SBMs) during the first week of treatment. The secondary end‐points included the median time of the first SBM, SBM frequency at weeks 2, 3 and 4, weekly response rate of SBMs, the stool consistency score and average number of complete spontaneous bowel movements (CSBMs) per week.Results: In total, 259 patients were randomized, with 130 in the lubiprostone group and 129 in the placebo group. SBM frequency was higher in the lubiprostone group (4.88 ± 4.09/wk) than that in the placebo group (3.22 ± 2.01/wk) at week 1 (P < 0.0001). SBM frequency was also higher in the lubiprostone group at weeks 2, 3 and 4. The average number of CSBMs and the stool consistency score in the lubiprostone group were significantly higher than that in the placebo group at each week. No drug‐related serious adverse events (AEs) occurred. The most commonly reported AE was nausea.Conclusion: Lubiprostone was superior to placebo in treating Chinese patients with functional constipation, together with good safety profile.
- 11 October 2021
- Published by Wiley in Journal of Digestive Diseases
- Vol. 22 (11) , 622-629
Efficacy and safety of lubiprostone for the treatment of functional constipation in Chinese adult patients: A multicenter, randomized, double‐blind, placebo‐controlled trial
Objectives: Functional constipation is a gastrointestinal disorder prevalent around the world. Lubiprostone is the first locally acting type‐2 chloride channel activator to be used for treating constipation. This study aimed to evaluate the efficacy and safety of lubiprostone in Chinese adults with functional constipation.Methods: This was a multicenter, randomized, double‐blind, placebo‐controlled study. Patients with functional constipation were randomized to receive either lubiprostone (24 mcg twice daily) or placebo for 4 weeks. The primary end‐point was the frequency of spontaneous bowel movements (SBMs) during the first week of treatment. The secondary end‐points included the median time of the first SBM, SBM frequency at weeks 2, 3 and 4, weekly response rate of SBMs, the stool consistency score and average number of complete spontaneous bowel movements (CSBMs) per week.Results: In total, 259 patients were randomized, with 130 in the lubiprostone group and 129 in the placebo group. SBM frequency was higher in the lubiprostone group (4.88 ± 4.09/wk) than that in the placebo group (3.22 ± 2.01/wk) at week 1 (P < 0.0001). SBM frequency was also higher in the lubiprostone group at weeks 2, 3 and 4. The average number of CSBMs and the stool consistency score in the lubiprostone group were significantly higher than that in the placebo group at each week. No drug‐related serious adverse events (AEs) occurred. The most commonly reported AE was nausea.Conclusion: Lubiprostone was superior to placebo in treating Chinese patients with functional constipation, together with good safety profile.
- Open Access
- 25 January 2020
- Published by Wiley in Molecular Oncology
- Vol. 14 (4) , 865-881
Prognostic significance of PD‐L1 expression on cell‐surface vimentin‐positive circulating tumor cells in gastric cancer patients
Although circulating tumor cells (CTCs) have shown promise as potential biomarkers for diagnostic and prognostic assessment in gastric cancer (GC), determining the predictive and prognostic value of programmed death‐ligand 1 (PD‐L1)‐positive CTCs in patients with GC is a challenge. Here, we identified that the expression of total vimentin (VIM) protein was positively correlated with PD‐L1 and inhibited CD8+ T‐cell activation in patients with GC according to bioinformatics analysis. Notably, coexpression of PD‐L1 and cell‐surface VIM (CSV) was detected by immunofluorescence and immunohistochemistry assay in locally advanced GC tumor specimens and metastatic lymph nodes. Likewise, CSV expression level was significantly decreased after transiently knocking down PD‐L1 in GC cell lines. Based on our established CTC detection platform, CTCs were isolated from peripheral blood samples collected from 70 patients (38 resectable and 32 unresectable) with GC using magnetic positive selection and a CSV‐specific monoclonal antibody, 84‐1. CSV+PD‐L1+CTCs were observed in 50 of 70 (71%) GC patient samples, ranging from 0 to 261 mL−1. A higher number of CSV+PD‐L1+CTCs were significantly associated with a short survival duration and poor therapeutic response. This study demonstrated that detection of PD‐L1+CTCs using a CSV‐enrichment method has promising value as a clinically relevant prognostic marker for GC.
- 25 January 2020
- Published by Wiley in Molecular Oncology
- Vol. 14 (4) , 865-881
Open AccessPrognostic significance of PD‐L1 expression on cell‐surface vimentin‐positive circulating tumor cells in gastric cancer patients
Although circulating tumor cells (CTCs) have shown promise as potential biomarkers for diagnostic and prognostic assessment in gastric cancer (GC), determining the predictive and prognostic value of programmed death‐ligand 1 (PD‐L1)‐positive CTCs in patients with GC is a challenge. Here, we identified that the expression of total vimentin (VIM) protein was positively correlated with PD‐L1 and inhibited CD8+ T‐cell activation in patients with GC according to bioinformatics analysis. Notably, coexpression of PD‐L1 and cell‐surface VIM (CSV) was detected by immunofluorescence and immunohistochemistry assay in locally advanced GC tumor specimens and metastatic lymph nodes. Likewise, CSV expression level was significantly decreased after transiently knocking down PD‐L1 in GC cell lines. Based on our established CTC detection platform, CTCs were isolated from peripheral blood samples collected from 70 patients (38 resectable and 32 unresectable) with GC using magnetic positive selection and a CSV‐specific monoclonal antibody, 84‐1. CSV+PD‐L1+CTCs were observed in 50 of 70 (71%) GC patient samples, ranging from 0 to 261 mL−1. A higher number of CSV+PD‐L1+CTCs were significantly associated with a short survival duration and poor therapeutic response. This study demonstrated that detection of PD‐L1+CTCs using a CSV‐enrichment method has promising value as a clinically relevant prognostic marker for GC.
- Open Access
- 1 March 2019
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 12, 195-203
Cathelicidin Suppresses Colon Cancer Metastasis via a P2RX7-Dependent Mechanism
- 1 March 2019
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 12, 195-203
Open AccessCathelicidin Suppresses Colon Cancer Metastasis via a P2RX7-Dependent Mechanism
- Open Access
- 16 February 2018
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 24 (3) , 662
Venous Thromboembolism in Hospitalized Inflammatory Bowel Disease Patients with Clostridium difficile Infection
To the Editor,
- 16 February 2018
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 24 (3) , 662
Open AccessVenous Thromboembolism in Hospitalized Inflammatory Bowel Disease Patients with Clostridium difficile Infection
To the Editor,
- Open Access
- 28 March 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (3) , e0174476
Expression of claudin-11, -23 in different gastric tissues and its relationship with the risk and prognosis of gastric cancer
Claudins play an important role in regulating the permeability of epithelial and endothelial cells and in the maintenance of cell polarity. We aimed to investigate expression of claudin-11, -23 in different gastric tissues and its relationship with clinicopathologic parameters and prognosis of gastric cancer. We compared their expression levels in the paired cancerous tissues versus those in the adjacent noncancerous tissues by real-time PCR, western blotting and immunohistochemistry. The results showed that the expression of claudin-11, -23 was greatly increased in paracancerous gastric tissue compared with cancerous tissue. We also compared their expression levels of tissues from gastric cancer, superficial gastritis, and atrophic gastritis by immunohistochemistry. The results indicated that the expression of claudin-11 and 23 was significantly higher in superficial gastritis than that in atrophic gastritis and gastric cancer. The expression of claudin-23 was significantly lower in atrophic gastritis than that in gastric cancer, but no obviously difference was observed for claudin-11. As for analysis of clinicopathologic parameters of gastric cancer, logistic multiple regression indicated that claudin-11 was significantly associated with sex, smoking, alcohol, H. pylori infection and Borrmann classification while claudin-23 was significantly associated with vessel cancer embolus. Cox multivariate survival analysis indicated that gastric cancer patients with negative claudin-23 expression had significantly longer overall survival. In conclusion, the expression of claudin-11, -23 was remarkably downregulated in gastric cancer. Abnormal expression of these proteins was significantly correlated with some clinicopathologic parameters. In particular, claudin-23 positive expression was associated with poor prognostic outcomes of gastric cancer patients and may therefore serve as an independent prognosticator of patient survival.
- 28 March 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (3) , e0174476
Open AccessExpression of claudin-11, -23 in different gastric tissues and its relationship with the risk and prognosis of gastric cancer
Claudins play an important role in regulating the permeability of epithelial and endothelial cells and in the maintenance of cell polarity. We aimed to investigate expression of claudin-11, -23 in different gastric tissues and its relationship with clinicopathologic parameters and prognosis of gastric cancer. We compared their expression levels in the paired cancerous tissues versus those in the adjacent noncancerous tissues by real-time PCR, western blotting and immunohistochemistry. The results showed that the expression of claudin-11, -23 was greatly increased in paracancerous gastric tissue compared with cancerous tissue. We also compared their expression levels of tissues from gastric cancer, superficial gastritis, and atrophic gastritis by immunohistochemistry. The results indicated that the expression of claudin-11 and 23 was significantly higher in superficial gastritis than that in atrophic gastritis and gastric cancer. The expression of claudin-23 was significantly lower in atrophic gastritis than that in gastric cancer, but no obviously difference was observed for claudin-11. As for analysis of clinicopathologic parameters of gastric cancer, logistic multiple regression indicated that claudin-11 was significantly associated with sex, smoking, alcohol, H. pylori infection and Borrmann classification while claudin-23 was significantly associated with vessel cancer embolus. Cox multivariate survival analysis indicated that gastric cancer patients with negative claudin-23 expression had significantly longer overall survival. In conclusion, the expression of claudin-11, -23 was remarkably downregulated in gastric cancer. Abnormal expression of these proteins was significantly correlated with some clinicopathologic parameters. In particular, claudin-23 positive expression was associated with poor prognostic outcomes of gastric cancer patients and may therefore serve as an independent prognosticator of patient survival.
- 26 April 2015
- Published by Springer Nature in Tumor Biology
- Vol. 36 (10) , 7521-7530
Expression of SIP1 is strongly correlated with LDHA and shows a significantly poor outcome in gastric cancer
Smad interacting protein 1 (SIP1) plays an important role in the epithelial-mesenchymal transition (EMT) process by downregulating E-cadherin. Lactate dehydrogenase A (LDHA) is a crucial enzyme that plays an important role in the final step of the Warburg effect by converting pyruvate to lactate irreversibly. EMT and Warburg effect are the hallmarks of advanced gastric cancer progression. Recently, EMT has been thought to be implicated in cancer metabolism. In this study, we want to find whether there was a correlation between the expressions of SIP1 and LDHA in gastric cancer and whether expression of SIP1 alone or in combination with LDHA is associated with the progression of gastric cancer. In the present study, we examined SIP1 and LDHA expression by immunohistochemistry analysis on tissue microarray (TMA) containing tumor tissues and matched non-neoplastic mucosa (NNM). Prognostic value and correlation with other clinicopathologic factors were evaluated. In this study, we investigated the expression of SIP1 and LDHA in 261 cancer tissues and their matched NNM using tissue microarray. The immunohistochemistry analysis showed that the expression of SIP1 and LDHA was significantly higher in cancer tissues than in NNM (P = 0.002 P = 0.000, respectively). The expression of SIP1was significantly associated with age, Lauren grade, and histologic differentiation (P < 0.05). The expression of SIP1 was strongly correlated with LDHA expression in gastric cancer (P = 0.000, R = 0.589). The combined expression of SIP1 and LDHA was significantly associated with age, Lauren grade, and histologic differentiation (P < 0.05). Survival analysis demonstrated that the expression of SIP1 or LDHA was associated with significantly shorter overall survival (OS) (P = 0.003, P = 0.000, respectively) and disease-free survival (DFS) (P = 0.003, P = 0.000, respectively). The combined expression of SIP1 and LDHA was associated with less survival time in gastric cancer patients (P = 0.000). The multivariate analysis showed that the expressions of SIP1 and LDHA in gastric cancer (GC) were independent prognostic factors for OS (hazard ratio = 1.465, 95 %CI 1.128–1.901, P = 0.004, hazard ratio = 1.514, 95 %CI 1.091–2.101 P = 0.013, respectively) and DFS (hazard ratio = 1.461, 95 %CI 1.130–1.890, P = 0.004, hazard ratio = 1.550 95 %CL1.119–2.147 P = 0.008, respectively). Our study indicated that expressions of SIP1 and LDHA are independent prognostic factors in gastric cancer patients and may be predictive of poor outcomes.
- 26 April 2015
- Published by Springer Nature in Tumor Biology
- Vol. 36 (10) , 7521-7530
Expression of SIP1 is strongly correlated with LDHA and shows a significantly poor outcome in gastric cancer
Smad interacting protein 1 (SIP1) plays an important role in the epithelial-mesenchymal transition (EMT) process by downregulating E-cadherin. Lactate dehydrogenase A (LDHA) is a crucial enzyme that plays an important role in the final step of the Warburg effect by converting pyruvate to lactate irreversibly. EMT and Warburg effect are the hallmarks of advanced gastric cancer progression. Recently, EMT has been thought to be implicated in cancer metabolism. In this study, we want to find whether there was a correlation between the expressions of SIP1 and LDHA in gastric cancer and whether expression of SIP1 alone or in combination with LDHA is associated with the progression of gastric cancer. In the present study, we examined SIP1 and LDHA expression by immunohistochemistry analysis on tissue microarray (TMA) containing tumor tissues and matched non-neoplastic mucosa (NNM). Prognostic value and correlation with other clinicopathologic factors were evaluated. In this study, we investigated the expression of SIP1 and LDHA in 261 cancer tissues and their matched NNM using tissue microarray. The immunohistochemistry analysis showed that the expression of SIP1 and LDHA was significantly higher in cancer tissues than in NNM (P = 0.002 P = 0.000, respectively). The expression of SIP1was significantly associated with age, Lauren grade, and histologic differentiation (P < 0.05). The expression of SIP1 was strongly correlated with LDHA expression in gastric cancer (P = 0.000, R = 0.589). The combined expression of SIP1 and LDHA was significantly associated with age, Lauren grade, and histologic differentiation (P < 0.05). Survival analysis demonstrated that the expression of SIP1 or LDHA was associated with significantly shorter overall survival (OS) (P = 0.003, P = 0.000, respectively) and disease-free survival (DFS) (P = 0.003, P = 0.000, respectively). The combined expression of SIP1 and LDHA was associated with less survival time in gastric cancer patients (P = 0.000). The multivariate analysis showed that the expressions of SIP1 and LDHA in gastric cancer (GC) were independent prognostic factors for OS (hazard ratio = 1.465, 95 %CI 1.128–1.901, P = 0.004, hazard ratio = 1.514, 95 %CI 1.091–2.101 P = 0.013, respectively) and DFS (hazard ratio = 1.461, 95 %CI 1.130–1.890, P = 0.004, hazard ratio = 1.550 95 %CL1.119–2.147 P = 0.008, respectively). Our study indicated that expressions of SIP1 and LDHA are independent prognostic factors in gastric cancer patients and may be predictive of poor outcomes.